PD32-03 tebipenem in vitro activity against a collection of pathogens responsible for urinary tract infections in the united states
Abstract
You have accessJournal of UrologyCME1 May 2022PD32-03 TEBIPENEM IN VITRO ACTIVITY AGAINST A COLLECTION OF PATHOGENS RESPONSIBLE FOR URINARY TRACT INFECTIONS IN THE UNITED STATES SJ Ryan Arends, Ian Critchley, Nicole Cotroneo, Jennifer Streit, Helio Sader, Mariana Castanheira, and Rodrigo Mendes SJ Ryan ArendsSJ Ryan Arends More articles by this author , Ian CritchleyIan Critchley More articles by this author , Nicole CotroneoNicole Cotroneo More articles by this author , Jennifer StreitJennifer Streit More articles by this author , Helio SaderHelio Sader More articles by this author , Mariana CastanheiraMariana Castanheira More articles by this author , and Rodrigo MendesRodrigo Mendes More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002583.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Enterobacterales (ENT)—especially Escherichia coli (EC), Klebsiella pneumoniae (KPN), and Proteus mirabilis (PM)—are widely implicated in urinary tract infections (UTIs). Many oral agents are used to manage UTIs, but their usefulness has been compromised by the increased prevalence of extended-spectrum β-lactamases (ESBL) and presence of co-resistance to trimethoprim-sulfamethoxazole (TMP/SMX) and quinolones. Tebipenem (TBP) is an oral carbapenem in clinical development for treating complicated UTIs and acute pyelonephritis. This study…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.